Arbutus Biopharma Corp [ABUS] stock is trading at $4.11, up 6.48%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ABUS shares have gain 9.02% over the last week, with a monthly amount drifted -3.52%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Arbutus Biopharma Corp [NASDAQ: ABUS] stock has seen the most recent analyst activity on February 02, 2022, when Jefferies upgraded its rating to a Buy but kept the price target unchanged to $5 for it. Previously, Jefferies started tracking the stock with Hold rating on February 25, 2021, and set its price target to $5. On December 17, 2020, H.C. Wainwright initiated with a Buy rating and assigned a price target of $10 on the stock. Robert W. Baird downgraded its rating to a Neutral. Wedbush upgraded its rating to Outperform for this stock on May 19, 2020. In a note dated March 06, 2020, Chardan Capital Markets upgraded an Buy rating on this stock but restated the target price of $5.
Arbutus Biopharma Corp [ABUS] stock has fluctuated between $1.69 and $4.72 over the past year. Currently, Wall Street analysts expect the stock to reach $8.5 within the next 12 months. Arbutus Biopharma Corp [NASDAQ: ABUS] shares were valued at $4.11 at the most recent close of the market. An investor can expect a potential return of 106.81% based on the average ABUS price forecast.
Analyzing the ABUS fundamentals
Arbutus Biopharma Corp [NASDAQ:ABUS] reported sales of 10.06M for the trailing twelve months, which represents a drop of -62.89%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -8.21%, Pretax Profit Margin comes in at -7.66%, and Net Profit Margin reading is -7.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.67 and Total Capital is -0.6. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.96 points at the first support level, and at 3.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.19, and for the 2nd resistance point, it is at 4.27.
Ratios To Look Out For
For context, Arbutus Biopharma Corp’s Current Ratio is 6.56. Further, the Quick Ratio stands at 6.56, while the Cash Ratio is 2.78. Considering the valuation of this stock, the price to sales ratio is 77.13, the price to book ratio is 6.33.
Transactions by insiders
Recent insider trading involved MANCHESTER KEITH S, Director, that happened on Aug 14 ’24 when 8846.0 shares were sold. Chief Medical Officer, Sims Karen completed a deal on Feb 02 ’24 to sell 4358.0 shares. Meanwhile, Chief Financial Officer HASTINGS DAVID C sold 9593.0 shares on Feb 02 ’24.
